Why does the rest of Lilly suffer?

Quote






























All FDE to be cut by Oct. Merger of NS/MSK/Cardio specialty, merger of MSK/NS PC- 20% or so of non FDE to be cut. Back to biads.

All contingent upon Alzheimer drug not getting moved forward for approval. Once that dog of a product is knocked out of pipeline changes/plan will be moved forward. Early retirement packages and buyout will be offered again but not as lucrative.

Times are about to get rough. Zyprexa sales eroding faster then predicting. Effient not anywhere close to what we had hoped for, Strattera sales flat, Axiron is small product and Cialis once daily not launching to expectations.

Diabetes to see big reductions regardless of above and that will take place by early summer. All FDE's gone.

Oncology safe for now- however with continued low CVM scores they are considering big shake up with new blood across division. Highest CVM scores in Psych will play out well for those reps.

Mens health untouched this year. They feel sized about right.
 


















Stop making everyone so nervous. If a reorganization occurs, an outside consultant / company handles it, so none of you have the insights that you think you do. Their is no greater security in any one division right now.
 






Anonymous said:
Stop making everyone so nervous. If a reorganization occurs, an outside consultant / company handles it, so none of you have the insights that you think you do. Their is no greater security in any one division right now.
Click to expand...

Who is suffering? Me, I'll tell you. Sure, I sip cognac and puff on a Cuban at the end of the day, looking out of my high rise penthouse office C-suite, and I lament about the 1% salary decrease... better me than you, though. I am that kind of guy. Next time you see me, kiss my feet, will you?
 






Anonymous said:
All FDE to be cut by Oct. Merger of NS/MSK/Cardio specialty, merger of MSK/NS PC- 20% or so of non FDE to be cut. Back to biads.

All contingent upon Alzheimer drug not getting moved forward for approval. Once that dog of a product is knocked out of pipeline changes/plan will be moved forward. Early retirement packages and buyout will be offered again but not as lucrative.

Times are about to get rough. Zyprexa sales eroding faster then predicting. Effient not anywhere close to what we had hoped for, Strattera sales flat, Axiron is small product and Cialis once daily not launching to expectations.

Diabetes to see big reductions regardless of above and that will take place by early summer. All FDE's gone.

Oncology safe for now- however with continued low CVM scores they are considering big shake up with new blood across division. Highest CVM scores in Psych will play out well for those reps.

Mens health untouched this year. They feel sized about right.
Click to expand...

I heard similar RUMOR about combining of MSK specialty/Cardio/Psych- no one but a very few really know what will go down. Nothing happening for sure until data for Alzheimer drug is released
 












Anonymous said:
Stop making everyone so nervous. If a reorganization occurs, an outside consultant / company handles it, so none of you have the insights that you think you do. Their is no greater security in any one division right now.
Click to expand...

WHO is making everyone nervous?

It rolls downhill, in case you haven't heard.

Look at the top of the heap for your scapegoat.
 










































Top Bottom
Back
Quote